LIGAND PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $6.49B
- P/E (TTM)
- 31.6
- Dividend yield
- –
About Ligand Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets, royalty assets, and related technologies. Its business model centers on acquiring, creating, and managing financial and intangible royalty rights across various drug development programs and partnered commercial therapies, alongside selling proprietary materials such as Captisol. The company enters into development and licensing agreements, service contracts, and collaborative partnerships with global biopharmaceutical firms and research partners to advance clinical-stage candidates and marketed products.
The company operates globally, with business partnerships and financial royalty exposure spanning the United States, Great Britain, Austria, and India. Ligand Pharmaceuticals maintains corporate office facilities in the United States, which serve as its primary operating and administrative headquarters for managing its extensive portfolio of biopharmaceutical partnerships, intellectual property assets, and licensing programs.
Summary of the business section of Ligand Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- LIGAND PHARMACEUTICALS INC
- Founded
- 1987
- Headquarters
- San Diego, CA
- Address
- 3911 Sorrento Valley Blvd, Suite 110 92121
- Phone
- (858) 550-7500
- Website
- ligand.com
- Employees
- 47, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst& YoungLLP, San Diego, California
Stock & identifiers
- Ticker
- LGND
- Other tickers
- LGNDZ, LGNXZ, LGNYZ, LGNZZ
- Exchange
- Nasdaq
- IPO date
- Nov 18, 1992
- Shares outstanding
- 20M, Aug 4, 2026
- Public float
- $1.60B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-6 reverse, Nov 19, 2010
- SEC CIK
- 886163
- CUSIP
- 53220K504
- ISIN
- US53220K5048
- LEI
- 5493008K7TB0IKP37H79
- EIN
- 77-0160744
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Todd C. Davis | Chief Executive Officer, Director | 199,513 |
| Andrew Reardon | CLO & Secretary | 36,514 |
| Octavio Espinoza | Chief Financial Officer | 48,818 |
| Martine Zimmermann | Director | 3,782 |
| Jason Haas | Director | 3,981 |
| Stephen L. Sabba | Director | 33,629 |
| John L. Lamattina | Director | 31,071 |
| Jason Aryeh | Director | 115,580 |
| John W. Kozarich | Director | 42,622 |
| Nancy Ryan Gray | Director | 8,930 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Todd C.Davis | $11.47M | $43.77M | $4.07M | $279 | $125 |
| FY2024 John L.Higgins | $0 | $0 | $6.58M | $158 | $93 |
| FY2024 Todd C.Davis | $12.91M | $21.71M | $6.58M | $158 | $93 |
| FY2023 John L.Higgins | $0 | $0 | $2.79M | $105 | $94 |
| FY2023 Todd C.Davis | $6.22M | $5.06M | $2.79M | $105 | $94 |
| FY2022 Davis | $5.20M | $4.98M | $3.85M | $99 | $90 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we have 47 full-time employees, of whom seven are involved directly in scientific research and development activities.”
Corporate history
Events identified from SEC filings